Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-25-101830
Filing Date
2025-04-29
Accepted
2025-04-29 07:28:43
Documents
14
Period of Report
2025-06-12

Document Format Files

Seq Description Document Type Size
1 DEF 14A d946596ddef14a.htm   iXBRL DEF 14A 418758
3 GRAPHIC g946596g01a46.jpg GRAPHIC 392416
4 GRAPHIC g946596g01a47.jpg GRAPHIC 293681
5 GRAPHIC g946596g96y27.jpg GRAPHIC 68031
  Complete submission text file 0001193125-25-101830.txt   2555744

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA sion-20241231.xsd EX-101.SCH 2498
16 EXTRACTED XBRL INSTANCE DOCUMENT d946596ddef14a_htm.xml XML 1248
Mailing Address 21 HICKORY DRIVE, SUITE 500 WALTHAM MA 02451
Business Address 21 HICKORY DRIVE, SUITE 500 WALTHAM MA 02451 617-819-2020
Sionna Therapeutics, Inc. (Filer) CIK: 0002036042 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-42504 | Film No.: 25882665
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)